Nucleocapsid Protein Boosts Humoral and Cellular Immune Responses Specific to Spike and RBD in Protein-Based SARS-CoV-2 Vaccination - Scorecard - DentalSpire

Nucleocapsid Protein Boosts Humoral and Cellular Immune Responses Specific to Spike and RBD in Protein-Based SARS-CoV-2 Vaccination

  • By

  • Stina Gröhn

  • Heini Lehto

  • Saana Soppela

  • Rauno A. Naves

  • Mikael A. Ritvos

  • Alina Iakubovskaia

  • Vili Lampinen

  • Iiris Mustonen

  • Sanniina Pakkala

  • Elizaveta Husu

  • Laura Kakkola

  • Ilkka Julkunen

  • Pekka Kolehmainen

  • Arja Pasternack

  • Olli Ritvos

  • Minna M. Hankaniemi

  • January 29, 2026

  • 0 min

Share

Clinical Scorecard: Nucleocapsid Protein Boosts Humoral and Cellular Immune Responses Specific to Spike and RBD in Protein-Based SARS-CoV-2 Vaccination

At a Glance

CategoryDetail
ConditionCOVID-19
Key MechanismsNucleocapsid protein enhances immune responses to spike and receptor-binding domain (RBD) proteins.
Target PopulationIndividuals at risk of SARS-CoV-2 infection.
Care SettingClinical settings for vaccination and immunization.

Key Highlights

  • SARS-CoV-2 vaccines induce systemic antibody responses but may not prevent infection.
  • Mucosal vaccines could enhance local immune responses and reduce transmission.
  • Nucleocapsid protein can improve humoral and cellular immunity against SARS-CoV-2.

Guideline-Based Recommendations

Diagnosis

  • Monitor for symptoms of COVID-19 and perform PCR or antigen tests for confirmation.

Management

  • Administer authorized COVID-19 vaccines to eligible populations.

Monitoring & Follow-up

  • Track vaccine efficacy and immune response over time.

Risks

  • Consider potential breakthrough infections despite vaccination.

Patient & Prescribing Data

Individuals receiving COVID-19 vaccinations.

Intranasal delivery of vaccines may enhance mucosal immunity.

Clinical Best Practices

  • Encourage vaccination in high-risk populations.
  • Consider mucosal vaccine strategies for improved local immunity.
  • Monitor immune responses post-vaccination for efficacy.

References

Original Source(s)

Nucleocapsid Protein Boosts Humoral and Cellular Immune Responses Specific to Spike and RBD in Protein-Based SARS-CoV-2 Vaccination

  • by Stina Gröhn, Heini Lehto, Saana Soppela, Rauno A. Naves, Mikael A. Ritvos, Alina Iakubovskaia, Vili Lampinen, Iiris Mustonen, Sanniina Pakkala, Elizaveta Husu, Laura Kakkola, Ilkka Julkunen, Pekka Kolehmainen, Arja Pasternack, Olli Ritvos, Minna M. Hankaniemi

  • January 29, 2026

Related Content

Monitoring Disease Outbreaks on Military Vessels Through Wastewater Surveillance: A Strategy for Deployed Armed Forces Members

Normalization of Seasonality and Age Distribution of Pediatric RSV Infection Following the Pandemic Disruption in the Netherlands

Effectiveness and Durability of the BNT162b2 KP.2 Vaccine Against COVID-19 Hospitalization and Emergency Department or Urgent Care Encounters in US Adults